China's Next-Generation Industrial Policy: Implications for Biotechnology and Life Sciences
A Rhodium Group assessment examines how Beijing's expanding state-directed industrial strategy is reshaping global supply chains and frontier technology competition, with notable consequences for biopharma, biomedicine, and biomedical innovation.
Introduction
A decade after the launch of Made in China 2025 (MIC25), China's industrial strategy has entered a new phase. Rather than retrenching in the face of domestic economic strain and international pushback, Beijing is expanding the scope and sophistication of state intervention across the economy. That is the central finding of China's Next-Generation Industrial Policy, a Rhodium Group report commissioned by the U.S. Chamber of Commerce and authored by Camille Boullenois, Malcolm Black, and Alessia Caruso.
For readers of The BioTech Review, the report is significant less for its broad macroeconomic conclusions than for what it reveals about the intersection of industrial policy, frontier technology, and biomedical innovation. Biotechnology, biopharmaceuticals, and clinical research now sit at a crossroads of supply chain security, national competitiveness, and healthcare delivery. Understanding how Beijing is repositioning its policy toolkit offers insight into how the global life sciences landscape may evolve over the coming decade.
This article summarizes the report's principal findings, situates them within the broader biotechnology context, and evaluates their implications for industry, clinical research, regulatory agencies, and global health.
Scientific Background
Industrial policy refers to deliberate government action to shape the structure and competitiveness of domestic industries. The MIC25 framework, introduced in 2015, targeted a defined set of strategic emerging industries, including advanced manufacturing, new energy vehicles, information and communications equipment, and biopharmaceuticals. The strategy's foundational planning document — commonly referred to as the Green Book — set out localization targets and a roadmap that drew sustained attention from international business groups.
In 2016, the Mercator Institute for China Studies (MERICS) published a widely cited analysis warning that if China succeeded with MIC25, foreign companies and industrial economies would face a powerful state-backed competitor across advanced manufacturing. In 2017, the European Union Chamber of Commerce in China and the U.S. Chamber of Commerce independently published assessments reaching similar conclusions: that the policy represented a shift away from market-oriented reform toward state-directed outcomes with broad implications for fair competition and global competitiveness.
The Rhodium Group report positions the present moment as a successor phase to MIC25. It argues that Chinese leadership views the earlier framework as substantially successful in building domestic capabilities, while remaining cognizant of persistent gaps in high-end semiconductors, advanced aerospace, and biomedicine. The current policy framework, the authors contend, is not a retreat but an expansion.
Research Findings
The report reaches two overarching conclusions. First, China's industrial policy is becoming more systemic and pervasive, extending across all layers of production — from upstream inputs and industrial equipment to downstream applications, services, and frontier technologies. The authors characterize this as a shift from targeted sectoral intervention to what they call an "industrial policy of everything."
Second, the domestic dynamics of this policy are accelerating China's trade dominance, deepening foreign dependence on Chinese supply chains, and enabling rapid global expansion by Chinese firms. The report describes a "China Shock 2.0," noting that China's manufacturing goods surplus has roughly doubled since 2019 to approximately $2 trillion, driven by both rising exports and successful import substitution.
Several findings are particularly relevant to the life sciences. The report notes that services — relatively neglected in earlier rounds of industrial policy — are receiving greater attention, with visible gains in software, data processing, and drug development. Artificial intelligence has emerged as a central pillar of the strategy, and the authors observe that frontier technologies are no longer treated solely as R&D priorities but are supported through public procurement and state-owned enterprises that generate demand for new products at scale.
The report also describes a more constrained macroeconomic environment in which this expanded policy is being pursued. Slowing growth, weak domestic demand, rising fiscal pressures, and declining capital allocation efficiency have prompted Beijing to recentralize financial resources. Government guidance funds are being consolidated and aligned more closely with national objectives, bank lending is steered through targeted relending facilities, and local-level subsidies are being culled. The authors caution that expanding industrial policy across an ever-wider set of sectors risks diluting its effectiveness, with evidence of strain already visible in declining corporate profitability, weakening private investment, and slowing R&D growth in key sectors.
Importantly for the biotechnology sector, the report identifies biomedicine as one of the areas where Chinese firms have not yet closed the technological gap. This distinguishes biopharmaceutical innovation from sectors such as new energy vehicles and information and communications equipment, where the report finds substantial progress in reducing import dependencies and displacing foreign competitors in domestic markets.
Industry Impact
The implications for the biotechnology industry are broad and differentiated by segment.
Pharmaceutical development and biomanufacturing. China's expanding role in active pharmaceutical ingredient (API) production, contract research, and contract development and manufacturing has already reshaped global pharmaceutical supply chains. The report's finding that industrial policy now extends to services, including drug development, suggests that these capacities will continue to grow and move up the value chain. For multinational pharmaceutical companies, this creates both efficiency opportunities and strategic dependency risks.
Investment and capital formation. The consolidation of government guidance funds and tighter direction of bank lending toward strategic priorities may increase capital availability for designated sectors, including biotech, while potentially reducing the efficiency of capital allocation. For venture capital and private equity investors, the report's observations suggest that the Chinese biotech financing environment will be increasingly shaped by state priorities rather than purely commercial signals.
Scientific collaboration. Deepening supply chain integration and state-directed industrial strategy may complicate cross-border research collaboration, particularly in areas deemed strategically sensitive. The report's framing of biomedicine as a sector of persistent technology gap is likely to reinforce incentives for domestic substitution and could affect licensing, technology transfer, and joint venture arrangements.
Global competitiveness. The report's description of rapid global expansion by Chinese firms in several sectors may serve as a template that could extend to biopharmaceuticals as domestic capabilities mature. For established biotechnology hubs in the United States, Europe, and Japan, this raises questions about long-term competitive positioning in areas such as generics, biosimilars, and increasingly complex biologics.
Regulatory and policy response. The report's recounting of the earlier MIC25 warnings — and their insufficient policy response — carries a pointed lesson. It suggests that credible analysis of industrial trajectories is available well in advance, but that the window for effective strategic action is finite.
Clinical & Regulatory Perspective
From a clinical and regulatory standpoint, the report's findings should be interpreted with care. The document is a policy analysis prepared for a business association, not a peer-reviewed scientific study. Its evidence base consists of trade data, policy documents, and expert interpretation rather than experimental or clinical data. Readers should distinguish between the well-documented macroeconomic trends it describes and the interpretive conclusions it draws about strategic intent.
Several considerations follow for the life sciences.
Regulatory status of technologies. The expansion of Chinese industrial policy into frontier technologies, including AI and drug development, occurs in markets with distinct regulatory frameworks. Pharmaceutical products developed in or for the Chinese market are subject to the National Medical Products Administration, while access to the U.S. and European markets requires compliance with the FDA and EMA. Divergence in regulatory expectations, data standards, and trial requirements remains a substantive barrier to the seamless global integration that the report's supply chain narrative might otherwise imply.
Clinical evidence and safety. Clinical data generated in any jurisdiction must satisfy the evidentiary standards of the regulators that will review it. The report does not address clinical evidence quality directly, and no conclusions about the safety or efficacy of specific therapies should be drawn from its findings.
Research limitations. The report acknowledges that China's policy execution has not been uniformly effective. Persistent gaps in biomedicine and high-end semiconductors indicate that industrial policy does not automatically produce technological leadership in fields that depend on deep foundational research, long development cycles, and complex regulatory pathways. This qualification is important: biomedical innovation has characteristics — including lengthy clinical validation, ethical oversight, and global regulatory coordination — that differ substantially from those of manufacturing sectors where state-led capacity expansion has proven more readily scalable.
Ethical considerations. State-directed investment in biomedical research and healthcare delivery raises questions about research ethics, data governance, and patient protections that the report does not examine in depth. These topics warrant dedicated attention from policymakers, bioethicists, and the international research community.
Areas requiring additional research. The relationship between industrial policy tools — guidance funds, procurement preferences, relending facilities — and actual biomedical innovation output remains understudied. Longitudinal research tracking patent quality, clinical trial design, and regulatory approval pathways in China's biopharmaceutical sector would help clarify whether policy intensity translates into clinically meaningful therapeutic progress.
Future Outlook
Over the next five to fifteen years, several developments appear plausible based on the trajectories the report identifies.
AI in biotechnology. The report places artificial intelligence at the center of China's frontier technology strategy, supported by public procurement and state enterprise adoption. In the life sciences, this could accelerate bioinformatics infrastructure, drug discovery platforms, and clinical decision support tools. However, the translation of AI investment into approved therapies remains an unproven proposition globally, and no jurisdiction has yet demonstrated that compute capacity alone substitutes for deep clinical validation.
Bioproduction and biomanufacturing. Expanding industrial policy into services and downstream applications, combined with existing upstream strengths in fermentation and chemical synthesis, suggests continued growth in China's biomanufacturing base. Whether this translates into leadership in advanced modalities such as cell and gene therapies is less certain.
Precision medicine and genomics. Population-scale genomics initiatives and companion diagnostics depend on large, well-characterized patient cohorts and robust data governance. Industrial policy may support infrastructure, but the clinical utility of these platforms will be determined by evidence generated through appropriately designed trials.
Global healthcare innovation. The report's core finding — that industrial policy is becoming broader and more consequential — implies that global healthcare supply chains will remain a subject of strategic competition. Multilateral coordination on regulatory standards, research integrity, and equitable access to therapies will be increasingly important.
Investment and ecosystem development. If China's biomedicine sector narrows its technology gap, capital flows into domestic biotech are likely to increase, potentially reshaping global licensing and partnership dynamics. Conversely, if the report's concerns about capital allocation efficiency materialize, investment returns may disappoint even as policy support intensifies.
Conclusion
The Rhodium Group report describes a significant and durable shift in how China organizes its industrial economy. For the biotechnology and life sciences community, the key findings are that biomedicine remains an area of unresolved technological gap; that policy support now extends into services and drug development; and that AI is being positioned as a central enabler of frontier innovation.
These developments warrant close, evidence-based monitoring rather than alarm or complacency. The historical record the report recounts — early, credible analysis followed by insufficient strategic response — is a caution against discounting long-horizon policy signals. At the same time, readers should recognize the limits of the present evidence: this is policy analysis, not clinical or experimental data, and the trajectory of biomedical innovation depends on factors — research integrity, regulatory science, ethical governance, and clinical validation — that no industrial policy can substitute for.
Continued investment in foundational research, transparent regulatory frameworks, and international scientific collaboration remains the most reliable path to long-term progress in biotechnology and global healthcare.